10-Q: Zymeworks Reports Q1 2025 Financial Results, Highlights Zanidatamab Progress and Pipeline Development

Zymeworks' Q1 2025 results show increased revenue driven by milestone payments and progress in clinical trials, alongside ongoing development of its wholly-owned pipeline.

Summary

• Zymeworks reported a net loss of $22.6 million for the three months ended March 31, 2025, with an accumulated deficit of $853.0 million.
• Revenue increased to $27.1 million, driven by milestone payments from GSK and Daiichi Sankyo, as well as development support and drug supply revenue from Jazz and BeiGene.
• Research and development expenses increased to $35.7 million, primarily due to expenses for ZW251 and other preclinical research activities.
• General and administrative expenses increased to $17.0 million, mainly due to increased stock-based compensation expense.
• The company had $321.6 million in cash resources as of March 31, 2025, which is expected to fund operations for at least the next twelve months.
• Zymeworks is advancing its wholly-owned pipeline, including ZW191 and ZW171, which are currently in Phase 1 clinical trials.
• Partner Jazz Pharmaceuticals reported $2.0 million in net product sales of Ziihera, resulting in $0.2 million in royalties for Zymeworks.
• The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending conditional marketing authorization of zanidatamab as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2+ (IHC 3+) BTC previously treated with at least one prior line of systemic therapy.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there's positive progress with zanidatamab and pipeline development, the company is still operating at a loss and faces significant risks.

Positives

• Revenue increased significantly due to milestone payments and royalties.
• Zanidatamab received a positive recommendation from the EMA CHMP.
• Wholly-owned pipeline programs ZW191 and ZW171 are progressing in Phase 1 clinical trials.
• Strong cash position expected to fund operations for at least the next twelve months.

Negatives

• The company reported a net loss of $22.6 million for the quarter.
• Research and development expenses increased, impacting profitability.
• The company is dependent on third parties for manufacturing and clinical trials.

Risks

• Clinical trials may be delayed or unsuccessful, impacting regulatory approval.
• The company faces competition from other pharmaceutical companies.
• The company relies on strategic partnerships, which may not be successful.
• The company may require substantial additional funding, which may not be available.
• The company is subject to various legal and regulatory risks.

Future Outlook

Zymeworks anticipates that its existing cash and cash equivalents and marketable securities as of March 31, 2025, will enable it to fund its operating expenditures and capital expenditure requirements for at least the next twelve months.

Management Comments

• With initial uptake in BTC in the United States, we look forward to reporting on the outcomes of the European Commissions review in the European Union (the EU), following the positive opinion from the CHMP, and pending regulatory action in China as early as 2Q-2025 with our partners Jazz Pharmaceuticals and BeiGene, as well as the top-line results from the HERIZON-GEA-01 study of Ziihera expected in 2H-2025.

Industry Context

Zymeworks operates in the competitive biopharmaceutical industry, focusing on developing novel, multifunctional biotherapeutics for cancer and autoimmune and inflammatory diseases, competing with major pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• Zymeworks' approach of using bispecific antibodies, such as zanidatamab, aligns with the industry trend of developing more targeted and effective therapies.
• The company's focus on HER2-expressing cancers positions it in a market with established players like Roche (Herceptin, Perjeta, Kadcyla) and Daiichi Sankyo (Enhertu), but Zymeworks aims to differentiate with its unique binding mechanism.
• Zymeworks' ADC candidates, like ZW191 and ZW220, compete with other ADCs in development for solid tumors, such as those from ImmunoGen (Elahere) and Seagen (Adcetris), but Zymeworks is using its proprietary TOPO1i payload technology to potentially improve efficacy and safety.
• The company's multispecific antibody therapeutics (MSATs), like ZW171, are part of a growing field of T cell engagers, competing with companies like Amgen (Blincyto) and Roche (Glofitamab), but Zymeworks is using its Azymetric platform to optimize tumor cell engagement and minimize off-tumor toxicities.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial performance and pipeline progress will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is critical to its success.
• Patients: The development of new therapies has the potential to improve patient outcomes.
• Strategic Partners: The success of strategic partnerships is important for the company's financial stability and development efforts.

Next Steps

• Continue patient recruitment in ongoing Phase 1 clinical trials for ZW191 and ZW171.
• Submit an IND to commence Phase 1 clinical studies for ZW251 by mid-2025.
• Submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2H-2026.
• Submit an IND to commence Phase 1 clinical studies for ZW209 in 1H-2026.
• Await the European Commission's review of zanidatamab's marketing authorization application.
• Monitor the top-line results from the HERIZON-GEA-01 study of Ziihera expected in 2H-2025.

Key Dates

Keywords

Zymeworks, zanidatamab, clinical trials, financial results, milestone payments, biotherapeutics, pipeline development, regulatory approval, Jazz Pharmaceuticals, ZW191, ZW171, GSK, Daiichi Sankyo, BeiGene